DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 205677/S-001

**SUPPLEMENT APPROVAL**

Vanda Pharmaceuticals, Inc.
Attention: Marlene Dressman, PhD
Vice President
2200 Pennsylvania Ave NW
Suite 300-E
Washington, DC 20037

Dear Dr. Dressman:

Please refer to your Supplemental New Drug Application (sNDA) dated October 7, 2014, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Hetlioz (tasimelteon) 20mg capsules.

This "Prior Approval" supplemental new drug application proposes the addition of the sentence "*The absolute oral bioavailability of tasimelteon is 38.3%.*" in section 12.3 of the full prescribing information. Other minor changes included in this supplement are as follows:

1. Replaced ™ symbol with ® symbol globally for HETLIOZ®.
2. Correction of typo in Prescribing Information from "6.1 Clinical Trial Experience" to "6.1 Clinical Trials Experience".
3. Correction of typo in Section 12.3 related to oral volume of distribution of tasimelteon at steady state from "56 – 126 L" to "59 – 126 L".
4. Correction of number of subjects enrolled in Study 2, Table 2, from "20" to "10" for each treatment group.

## APPROVAL & LABELING

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

## CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Dr. Brendan Muoio, Regulatory Project Manager, at (240) 402-4518.

Sincerely,

*{See appended electronic signature page}*

Mitchell V. Mathis, MD
CAPT, USPHS
Director
Division of Psychiatry Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

---

**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**

---

/s/

---

MITCHELL V Mathis
12/12/2014